Crohn’s Disease Patients Refractory Tumor Necrosis

Crohn’s Disease Patients Refractory To Tumor Necrosis Factor Inhibitors
The Herald |
Crohn’s disease, SPRING HOUSE, PA., OCT. 17, 2012 — /PRNewswire/ — Findings from a Janssen Research & Development, LLC (Janssen)-sponsored Phase 2b trial evaluating the efficacy and safety of STELARA® (ustekinumab) in the treatment of moderate to severe Crohn’s disease appeared today in The New England Journal of Medicine.The results showed that among patients who had previously failed or were intolerant to at least one (TNF) antagonist, a significantly greater proportion receiving intravenous (I.V.) STELARA 6 mg/kg achieved the primary endpoint of clinical response at week 6, defined as a 100-point reduction in the Crohn’s (CDAI), compared with patients receiving placebo (40 percent vs. 24 percent, respectively).  Subsequent maintenance therapy with every eight-week subcutaneous (SC) STELARA among I.V. STELARA induction responders resulted in significantly higher rates of clinical remission at week 22 compared with placebo.  STELARA targets interleukin (IL)-12 and IL-23, cytokines believed to play a role in immune-mediated including Crohn’s disease.   

Read more here:

Psoriasis Drug May Help People With Crohn’s Disease: StudyDoctors Lounge
Study Finds Potential New Drug Therapy for Crohn’s DiseaseUCSD Medical Center

Leave a Reply